Biotech RadarJobs updated

COMPANY

Stoke Therapeutics

HQ: Bedford, MA source · stoketherapeutics.com ↗ · New England

Clinical Phase 3

19 open jobs · last seen Oct 23, 2026 · 5 sources

Keywords: optic atrophy optic nerve disease neurology Dravet syndrome zorevunersen zorevunersen (STK-001) STK-001

Location: Bedford, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

19Open jobs3Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Vice President, Translational DevelopmentBedford, Massachusetts, United StatesOct 21, 2026Oct 22, 2026
Vice President/Senior Vice President, Genomics & Data ScienceBedford, Massachusetts, United StatesOct 21, 2026Oct 22, 2026
Vice President, Non Clinical DevelopmentBedford, Massachusetts, United StatesOct 21, 2026Oct 22, 2026
Vice President, Pharmaceutical & Process DevelopmentBedford, Massachusetts, United StatesOct 21, 2026Oct 22, 2026
Senior Director, National Accounts - NortheastRemoteOct 21, 2026Oct 22, 2026

See all 19 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (19 open jobs at last check). source ↗
  2. Trial start Phase 3: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome source ↗
  3. Partnership Partnership / licensing: $165M (upfront, as published); deal value up to $385M (kept separate from upfront), announced Feb 18, 2025. Source: SEC filing. source ↗
  4. Trial start Phase 2: An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome source ↗
  5. Trial start Phase 1/Phase 2: An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 19

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Vice President, Translational DevelopmentBedford, Massachusetts, United StatesOct 21, 2026Oct 22, 2026Not stated
Vice President/Senior Vice President, Genomics & Data ScienceBedford, Massachusetts, United StatesOct 21, 2026Oct 22, 2026Not stated
Vice President, Non Clinical DevelopmentBedford, Massachusetts, United StatesOct 21, 2026Oct 22, 2026Not stated
Vice President, Pharmaceutical & Process DevelopmentBedford, Massachusetts, United StatesOct 21, 2026Oct 22, 2026Not stated
Senior Director, National Accounts - NortheastRemoteOct 21, 2026Oct 22, 2026Not stated
Manager, Regulatory Affairs, CMCBedford, Massachusetts, United StatesOct 20, 2026Oct 21, 2026Not stated
Vice President, Regulatory Strategy and CMCBedford, Massachusetts, United StatesOct 7, 2026Oct 9, 2026Executive
Senior Manager/Associate Director, Legal OperationsBedford, Massachusetts, United StatesOct 7, 2026Oct 9, 2026Senior
Lab AssistantBedford, Massachusetts, United StatesOct 1, 2026Oct 9, 2026Entry
Senior Scientist, Sterile Oligonucleotide Drug Product DevelopmentBedford, Massachusetts, United StatesSep 28, 2026Oct 9, 2026Senior
Associate Director, Commercial Supply Chain Management & PlanningBedford, Massachusetts, United StatesSep 25, 2026Oct 9, 2026Senior
Executive Director, State Government AffairsBedford, Massachusetts, United StatesSep 22, 2026Oct 9, 2026Executive
Senior Director, ToxicologyBedford, Massachusetts, United StatesSep 22, 2026Oct 9, 2026Senior
Senior Director, Quality ControlBedford, Massachusetts, United States; HybridSep 22, 2026Oct 9, 2026Senior
Director, Global Regulatory AffairsBedford, Massachusetts, United StatesSep 18, 2026Oct 9, 2026Senior
Senior Clinical Trial ManagerHybridAug 12, 2026Oct 20, 2026Not stated
Vice President, Strategic Sourcing & ProcurementBedford, Massachusetts, United StatesAug 12, 2026Oct 9, 2026Executive
Director, Clinical Data ManagementBedford, Massachusetts, United StatesAug 10, 2026Oct 9, 2026Senior
Senior Director, Investor RelationsBedford, Massachusetts, United StatesJul 10, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Last 2 years.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT06872125A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromePhase 3RecruitingJun 4, 20252027-03 (estimated)
NCT04740476An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromePhase 2Active, not recruitingJan 20, 2021Mar 31, 2029 (estimated)
NCT04442295An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromePhase 1/Phase 2CompletedJun 29, 2020Nov 14, 2023 (actual)
Feedback